About 1,000 cases of the respiratory illness caused by Enterovirus D68 have been confirmed in 10 states in the United States so far. Many of these children are being hospitalized for it.
There are more than 100 different enteroviruses, according to Dr Brady. “They typically are prevalent in the summer season in non-tropical regions and year-round in tropical regions,” he said. “They can cause different clinical syndromes. For example, polio is caused by 3 different enteroviruses, poliovirus 1, poliovirus 2 and poliovirus 3. However, most enterovirus infections cause respiratory infections, such as sore throats and herpangina [mouth blisters]. Enteroviruses can cause hand, foot and mouth syndrome and viral meningitis.”
The enterovirus, Enterovirus D68, causing this outbreak was first identified in 1962, according to Dr Brady, however, he suspects that it was around prior to that date.
What was unusual in this outbreak was that many children’s hospitals around the country were noticing a significant increase in the number of children coming to the emergency rooms for respiratory infections; and many needed to be admitted to the hospital, according to Dr Brady.
“The hospital census was starting to appear like what is typically seen during the winter respiratory virus season,” he said. “Many of the hospitalized children had severe respiratory disease-hypoxia, difficulty breathing and wheezing. While some of the hospitalized children were previously healthy, the majority had a history of wheezing or asthma. The mean age of the children was between 4 and 5 years of age. These ages are older than we usually see during the winter season.”
This outbreak was unique because it occurred in the summer season; was caused by a rare enterovirus; affected older aged children; and had a greater impact on those with history of wheezing or asthma.
“This is probably not a priority for formulary managers,” Dr Brady said. “There’s no specific antimicrobial therapy. Treatments are standard for severe respiratory tract infections and wheezing.”
Related:
Experience Brief: Femoral nerve block reduces hospital admissions, opioids in pediatrics
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More